ReWalk Robotics (NASDAQ:LFWD) Price Target Lowered to $4.50 at Lake Street Capital

ReWalk Robotics (NASDAQ:LFWD) had its price objective decreased by Lake Street Capital from $6.00 to $4.50 in a research report sent to investors on Thursday morning,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

Other equities analysts have also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of ReWalk Robotics in a report on Thursday. Laidlaw initiated coverage on ReWalk Robotics in a report on Monday, February 10th. They set a “buy” rating and a $10.00 price target for the company.

ReWalk Robotics Stock Down 4.1 %

Shares of LFWD opened at $1.77 on Thursday. ReWalk Robotics has a 52-week low of $1.25 and a 52-week high of $7.70. The company has a market capitalization of $18.76 million, a PE ratio of -0.71 and a beta of 2.05. The stock has a fifty day simple moving average of $1.74 and a two-hundred day simple moving average of $2.40.

Insider Transactions at ReWalk Robotics

In related news, Director Michael Swinford bought 21,622 shares of the stock in a transaction on Monday, November 25th. The shares were bought at an average cost of $2.03 per share, for a total transaction of $43,892.66. Following the purchase, the director now owns 65,040 shares of the company’s stock, valued at $132,031.20. This trade represents a 49.80 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Global Fund Lp Lind II sold 381,676 shares of ReWalk Robotics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $3.36, for a total value of $1,282,431.36. Following the completion of the transaction, the insider now owns 1,049,430 shares in the company, valued at $3,526,084.80. This trade represents a 26.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.50% of the company’s stock.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.